Efficacy and Tolerability of Sertaconazole Nitrate in Mycotic Vaginitis

Abstract

Objectives: In this research, single-dose of 300 mg sertaconazole nitrate ovule in mycotic vaginitis has been evaluated in terms of clinical and microbiological efficacy and safety. Patients and Methods: The study included 177 patients (mean age 31.8±7.8 years; range 15 to 53 years) who applied to our polyclinics with vaginitis complaints. Patients having cottage cheese-like discharge, vaginal pH<4.5, Whiff test (-) were accepted as mycotic vaginitis. To determine mycotic agents in vaginal discharge, samples were cultured in Sabouraud glucose agar. As a treatment, patients were administered a single-dose of 300 mg sertaconazole nitrate ovule. Its clinical and microbiological aspects have been evaluated in the first visit, a week after and finally one month after the first visit. Symptoms related to vaginitis, clinical and microbiological recovery rates and adverse effects have been noted. Results: All symptom scores were significantly lower in the second visit, and all except dysuria complaint in the third visit. Clinical recovery rates in the second and third visit were in 76.0% and 79.5%. According to mycotic culture test results, the microbiologic recovery rates were 88.8% in the second and 91.4% in the third visits. Conclusion: Single-dose sertaconazole nitrate ovule was evaluated as a convenient, symptom-relieving and safe treatment for mycotic vaginitis. Turkish Başlık: Mikotik Vajinitlerde Sertakonazol Nitratın Etkinliği ve Tolerabilitesi Anahtar Kelimeler: Mikotik vajinit; sertakonazol nitrat; etkinlik ve tolerabilite. Amaç: Bu çalışmada tek doz 300 mg sertakonazol nitrat ovul'un mikotik vajinitlerde klinik ve mikrobiyolojik etkinliği, uygunluğu ve güvenilirliliği değerlendirildi. Hastalar ve Yöntemler: Polikliniğimize vajinit yakınması ile başvuran 117 olgu (ort. yaş 31.8±7.8; dağılım 15-53) incelemeye alındı. Çökelek tarzı akıntısı olan, vajinal pH<4.5, Whiff testi (-) saptanan olgular mikotik vajinit olarak kabul edildi. Bu olgulardaki mikotik ajanları tespit etmek amacıyla akıntı örnekleri Sabouraud glukoz agar besi yerine ekim yapıldı. Tedavi olarak olguların tek doz 300 mg sertakonazol nitrat ovul kullanmaları istendi. Klinik ve mikrobiyolojik olarak tüm olgular ilk vizitte, bir hafta sonra ve son olarak bir ay sonra tekrar değerlendirildi. Vajinit ile ilgili semptom skorları, klinik ve mikrobiyolojik iyileşme oranları ve yan etkileri kaydedildi. Bulgular: Olguların semptom skorları incelendiğinde ikinci vizitte tüm semptomlarda üçüncü vizitte ise dizüri şikayetleri dışındaki semptomlarda anlamlı ölçüde azalma saptandı. Klinik iyileşme oranları ikinci ve üçüncü vizitte %76.0 ve %79.5 olarak saptandı. İkinci ve üçüncü vizitteki mikrobiyolojik iyileşme oranları ise %88.8 ve %91.4 olarak belirlendi. Sonuç: Tek doz sertakonazol nitrat ovul vajinal mikoz tedavisinde kolay uygulanabilir, etkili ve güvenilir olarak değerlendirildi.: Tek doz sertakonazol nitrat ovul vajinal mikoz tedavisinde kolay uygulanabilir, etkili ve güvenilir olarak değerlendirildi.

Keywords

• Mycotic vaginitis; sertaconazole; efficacy and tolerability.

Mikotik Vajinitlerde Sertakonazol Nitratın Etkinliği ve Tolerabilitesi

Öz

Amaç: Bu çalışmada tek doz 300 mg sertakonazol nitrat ovul’un mikotik vajinitlerde klinik ve mikrobiyolojik etkinliği, uygunluğu ve güvenilirliliği değerlendirildi. Hastalar ve Yöntemler: Polikliniğimize vajinit yakınması ile başvuran 117 olgu (ort. yaş 31.8±7.8; dağılım 15-53) incelemeye alındı. Çökelek tarzı akıntısı olan, vajinal pH

Anahtar Kelimeler

• Mikotik vajinit, sertakonazol nitrat, etkinlik ve tolerabilite

Kaynakça

1. 1. Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J 1979;55:645-7.
2. 2. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985;152:924-35.
3. 3. Foxman B, Marsh JV, Gillespie B, Sobel JD. Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. J Womens Health 1998;7:1167-74.
4. 4. Erkaya S, Sipahi T, Özen M, Kutlar İ, Tarikâhya Y. Vulvovajinal kandidiazis tedavisinde tek doz flukonazol ile 5 gün süreli ketokonazol kullanımının karşılaştırılması. Anatolian J Gynecol Obst 1994; 4:41-5.
5. 5. Larone DH. Medically important fungi: a guide to identification. 4th ed. Washington: ASM Press; 2002.
6. 6. Reef SE, Levine WC, McNeil MM, Fisher-Hoch S, Holmberg SD, Duerr A, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis 1995; 20 Suppl 1:S80-90.
7. 7. Dellenbach P, Thomas JL, Guerin V, Ochsenbein E, Contet-Audonneau N. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet 2000;71 Suppl 1:S47-52.
8. 8. Lebherz T, Guess E, Wolfson N. Efficacy of single- versus multiple-dose clotrimazole therapy in the management of vulvovaginal candidiasis. Am J Obstet Gynecol 1985;152:965-8.

9. 9. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG 2002;109:85-95.
10. 10. Lawrence AG, Houang ET, Hiscock E, Wells MB, Colli E, Scatigna M. Single dose therapy of vaginal candidiasis: a comparative trial of fenticonazole vaginal ovules versus clotrimazole vaginal tablets. Curr Med Res Opin 1990;12:114-20.
11. 11. Kjaeldgaard A. Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis. Pharmatherapeutica 1986; 4:525-31.
12. 12. Wang PH, Chao HT, Chen CL, Yuan CC. Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. J Chin Med Assoc 2006;69:259-63.
13. 13. Quereux C, Gelas B, Chevallier T, Petit F, Micheletti MC. Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil 2000;28:238-44. [Abstract]
14. 14. Palacín C, Sacristán A, Ortiz JA. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung 1992;42:711-4.
15. 15. Torres-Rodriguez JM, Alayeto J, Palacin C, Alia C. Evaluation de deux nouveaux antimycosiques imidazoliques in vitro sur levures, dermatophytes et Scopulariopsis. Bull Soc Fr Mycol Med 1986;15(2.): 529-532. [Abstract]
16. 16. Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneimittelforschung 1992;42:705-10. 17. Palacin C, Datos internos. Ferrer Internacional Centro de Investigacion; 1994.
17. 18. Carrillo-Muñoz AJ, Torres-Rodriguez JM. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J Antimicrob Chemother 1995;36:713-6.
18. 19. Martin-Mazuelos E, Aller AI, Morilla D, Montero O. Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. Chemotherapy 1996; 42:112-7.
19. 20. Azcona O, Torrent J, Verges J, Marquez M, Albet C, Ortiz JA, et al. Tolerance and kinetic behavior after single and repeated vaginal administration of sertaconazole cream and tablets in healthy volunteers. Current Therap Res 1991;49:1046-60.